Advanced Proteome Therapeutics Files Provisional LP for Compounds Targeting SARS-COV-2
mcleanap2021-09-09T13:06:08-04:00Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has filed for patent protection on a family of therapeutic candidates against SARS-CoV-2, the virus which causes COVID-19 and has initiated a project to rapidly manufacture test quantities of these drugs.